Vertex Pharmaceuticals Incorporated Message Board

This morning BofA upgraded to Neutral from Sell and maintaining their $29 tgt based on valuation.

In the past they misrepresented data wrt the effect of trial dropouts, and their credibility is low, but we should see some short-covering.